Physician

Joyce Ann O'Shaughnessy, MD

According to 2025 Medicare claims, Joyce O'Shaughnessy, MD (NPI: 1790727709) practices medical oncology in the Dallas-Plano-Irving, TX market, with the plurality of this provider's patient population coming from Dallas, TX. This provider's primary affiliated billing organization is TEXAS ONCOLOGY PA (NPI: 1003083445; TIN: 752131429) and primary practice location at 75246-2012.

O'Shaughnessy's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 858 traditional Medicare patients, billed 153,554 HCPCS/CPT codes, and received $2,836,128 in Medicare payments. The top billing code was 96413 (Administration of chemotherapy into vein, 1 hour or less). Part D data shows 2,112 prescription claims across 393 beneficiaries totaling $2,028,524 in drug costs, led by Verzenio (Abemaciclib). DME data shows 96 claims. Open Payments data shows 541 records totaling $2,257,253. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has risen steadily, from $1,167,993 to $2,836,128. Similarly, Part D prescription costs have risen steadily, from $478,407 to $2,028,524. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	369	93,868	$1,167,993
2016	585	118,072	$1,614,410
2017	545	66,884	$1,260,566
2018	529	80,039	$1,515,172
2019	742	112,927	$1,953,268
2020	586	88,614	$1,499,825
2021	810	104,400	$1,744,426
2022	881	117,912	$2,258,355
2023	864	174,071	$3,429,629
2024	858	153,554	$2,836,128

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	222	1,601	$478,407
2016	253	2,190	$904,539
2017	298	2,553	$1,080,457
2018	334	2,697	$1,084,993
2019	361	2,726	$1,527,156
2020	379	2,795	$1,487,303
2021	395	2,381	$1,539,373
2022	374	2,133	$1,709,786
2023	370	2,116	$2,004,718
2024	393	2,112	$2,028,524

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	22	173	$123,212
2016	N/R	156	$71,795
2017	47	205	$53,399
2018	40	153	$26,096
2019	24	123	$14,787
2020	76	284	$21,403
2021	41	196	$12,950
2022	24	101	$4,752
2023	N/R	85	$20,795
2024	N/R	96	$4,273

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
96413	Administration of chemotherapy into vein, 1 hour or less	245	440	$100
96375	Injection of additional new drug or substance into vein	154	409	$12
80053	Blood test, comprehensive group of blood chemicals	319	709	$10
36415	Insertion of needle into vein for collection of blood sample	315	698	$9
85025	Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count	311	668	$8

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Verzenio	Abemaciclib	80	2,121	$1,103,390
Ibrance	Palbociclib	33	924	$502,722
Anastrozole	Anastrozole	552	46,629	$11,122
Xarelto	Rivaroxaban	13	630	$10,068
Letrozole	Letrozole	430	32,454	$9,514

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
L8000	Breast prosthesis, mastectomy bra, without integrated breast prosthesis form, any size, any type	N	N/R	12	$1,561
J8521	Capecitabine, oral, 500 mg	N	N/R	26	$902
E0656	Segmental pneumatic appliance for use with pneumatic compressor, trunk	Y	N/R	16	$687
E0657	Segmental pneumatic appliance for use with pneumatic compressor, chest	Y	N/R	16	$653
Q0511	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for the first prescription in a 30-day period	N	N/R	26	$470

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	100	$116,999	Merck Sharp & Dohme LLC
Research Payments	Reported research-related payment or transfer-of-value amount.	441	$2,140,255	AstraZeneca Pharmaceuticals LP
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Joyce Ann O'Shaughnessy, MD?

Tedicare shows public-source Medicare data for Joyce Ann O'Shaughnessy, MD (NPI 1790727709), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Joyce Ann O'Shaughnessy, MD have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Joyce Ann O'Shaughnessy, MD?

Joyce Ann O'Shaughnessy, MD is linked to TEXAS ONCOLOGY PA (billing NPI 1003083445) in the available physician profile data.

Does Joyce Ann O'Shaughnessy, MD have Open Payments data?

Joyce Ann O'Shaughnessy, MD has 541 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.